

# Diabetic foot osteomyelitis



*Ilker Uçkay*



UNIVERSITÉ DE GENÈVE  
FACULTÉ DE MÉDECINE

HUG    
Hôpitaux Universitaires de Genève



Symposium zum Diabetischen Fuss  
27. Nov. 2015  
6w

Symposium zum Diabetischen Fuss  
27. Nov. 2015

'Sausage toe'





Symposium zum Diabetischen Fuss  
27. Nov. 2015

Illustration reproduced with permission from Clinical Publishing Ltd, Oxford



Symposium zum Diabetischen Fuss  
27. Nov. 2011

**Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients.**

Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. 1985


Prospectively.

Osteomyelitis defined histopathologically and/or clinically.

Sensitivity of 66%, specificity of 85%, positive predictive value of 89%, and a negative predictive value of 56%.

# Who has an osteomyelitis ?

**Figure.** Study Selection



**Table 2.** Diagnostic Accuracy of Physical Examination and Laboratory Investigations for Lower Extremity Osteomyelitis in Patients With Diabetes Mellitus

Source	Examination Maneuver/Finding	Positive LR (95% CI)	Negative LR (95% CI)
<b>Signs</b>			
Lavery et al, 2007 <sup>30</sup>	Positive probe-to-bone finding <sup>a</sup>	9.4 (6.1-15)	0.15 (0.06-0.37)
Grayson et al, 1995 <sup>10</sup>	Positive probe-to-bone finding <sup>a</sup>	4.3 (1.7-10)	0.40 (0.26-0.61)
Shone et al, 2006 <sup>26</sup>	Positive probe-to-bone finding <sup>a</sup>	4.5 (1.8-11)	0.68 (0.48-0.95)
Summary LR		6.4 (3.6-11)	0.39 (0.20-0.76)
Newman et al, 1991 <sup>9</sup>	Bone exposure <sup>a</sup>	9.2 (0.57-146)	0.70 (0.53-0.92)
Newman et al, 1991 <sup>9</sup>	Ulcer area >2 cm <sup>2a</sup>	7.2 (1.1-49)	0.48 (0.31-0.76)
Newman et al, 1991 <sup>9</sup>	Ulcer inflammation (erythema, swelling, purulence) <sup>a</sup>	1.5 (0.51-4.7)	0.84 (0.56-1.3)
<b>Clinical Gestalt</b>			
Newman et al, 1991 <sup>9</sup>	Clinical judgment <sup>a</sup>	9.2 (0.57-147)	0.70 (0.53-0.92)
Vesco et al, 1999 <sup>40</sup>	Wagner grade >2 <sup>a</sup>	13 (0.82-203)	0.48 (0.27-0.86)
Enderle et al, 1999 <sup>24</sup>	Wagner grade >2 <sup>a</sup>	3.9 (0.96-16)	0.04 (0-0.70)
Summary LR <sup>b</sup>		5.5 (1.8-17)	0.54 (0.30-0.97)
<b>Laboratory Findings</b>			
Kaletka et al, 2001 <sup>36</sup>	ESR ≥70 mm/h	19 (1.3-290)	0.13 (0.04-0.42)
Newman et al, 1991 <sup>9</sup>	ESR >70 mm/h <sup>a</sup>	6.4 (0.39-105)	0.74 (0.54-1.0)
Summary LR <sup>c</sup>		11 (1.6-79)	0.34 (0.06-1.9)
Oyen et al, 1992 <sup>38</sup>	Swab culture <sup>d</sup>	1 (0.65-1.5)	1 (0.08-13)



Method (Grayson, *JAMA* 1995):

Interpretation: Key issue  
is pre-test probability

- Helps R/O DFO when low
- Helps confirm when high





Symposium zum Diabetischen Tag 2015  
27. Nov. 2015

Date: 7/15/02 Site: Right Hand

Client: [REDACTED]

I.D.#: 4744






L 1.7 x W 3.5 x D 1.4 cm

Wound 0213

cm	0	1	2	3	4	5
----	---	---	---	---	---	---

Symposium zum Diabetischen Fuss  
27. Nov. 2015





Symposium zum Diabetestage 2015  
27. Nov. 2015  
Fuss



*Courtesy: E. Senneville, MD*

# Culture of Percutaneous Bone Biopsy Specimens for Diagnosis of Diabetic Foot Osteomyelitis: Concordance with Ulcer Swab Cultures

Eric Senneville,<sup>1</sup> Hugues Melliez,<sup>1</sup> Eric Beltrand,<sup>2</sup> Laurence Legout,<sup>1</sup> Michel Valette,<sup>1</sup> Marie Cazaubiel,<sup>1</sup> Muriel Cordonnier,<sup>1</sup> Michèle Caillaux,<sup>1</sup> Yazdan Yazdanpanah,<sup>1</sup> and Yves Mouton<sup>1</sup>

<sup>1</sup>Diabetic Foot Clinic and <sup>2</sup>Department of Orthopedic Surgery, Dron Hospital, Tourcoing, France

**Table 3. Proportion of pathogens isolated from cultures of bone biopsy and/or swab samples obtained from 69 patients with diabetes with suspected foot osteomyelitis.**

Pathogen	Total	No. of instances in which culture yielded the specified pathogen			Concordance, <sup>a</sup> %
		From bone biopsy sample only	From swab sample only	From both bone biopsy and swab samples	
<i>Staphylococcus aureus</i>	49	13	15	21	42.8
CNS	35	30	4	1	2.8
Streptococci <sup>b</sup>	31	11	12	8	25.8
Enterococci	15	9	5	1	6.67
Corynebacteria	10	2	8	0	0
Gram-negative bacilli	42	12	18	12	28.5
Anaerobes	9	6	3	0	0
Total	191	79	65	43	22.5

# Needle Puncture and Transcutaneous Bone Biopsy Cultures Are Inconsistent in Patients with Diabetes and Suspected Osteomyelitis of the Foot

Eric Senneville,<sup>1</sup> Hélène Morant,<sup>4</sup> Dominique Descamps,<sup>4</sup> Sophie Dekeyser,<sup>4</sup> Eric Beltrand,<sup>2</sup> Bruno Singer,<sup>5</sup> Michèle Caillaux,<sup>3</sup> Arnaud Boulogne,<sup>6</sup> Laurence Legout,<sup>1</sup> Xavier Lemaire,<sup>1</sup> Christine Lemaire,<sup>6</sup> and Yazdan Yazdanpanah<sup>1</sup>

<sup>1</sup>Diabetic Foot Clinic, <sup>2</sup>Department of Orthopedic Surgery, and <sup>3</sup>Laboratory of Microbiology, Gustave Dron Hospital, Tourcoing, and <sup>4</sup>Laboratory of Microbiology, <sup>5</sup>Department of Radiology, and <sup>6</sup>Diabetic Foot Clinic, General Hospital, Béthune, France

**Table 2. Proportion of microorganisms isolated from bone biopsy specimens and needle puncture specimens obtained concomitantly from 31 patients with diabetes and suspected osteomyelitis of the foot.**

Microorganism isolated	No. of cultures			Correlation, <sup>a</sup> %
	Total	Bone biopsy specimen only	Needle puncture specimen only	
<i>Staphylococcus aureus</i>	15	7	1	46.7
Coagulase-negative staphylococci	11	3	8	0
Other gram-positive cocci <sup>b</sup>	8	3	4	14.3
Gram-negative bacilli	25	10	9	24.0
Anaerobes <sup>c</sup>	8	3	3	25.0
Total	67	26	25	23.9

# In Which Situations Is Diagnostic Bone Biopsy Most Recommended?

- Failure to *respond* to empiric antibiotic therapy
- Plan to insert *metalware* in bone at affected site
- Desire to use antibiotic *agents* that may be especially effective for osteomyelitis but have a high potential for selecting resistant bacteria





Symposium zum Diabetischen Fuss  
27. Nov. 2015

**Chronic post-traumatic osteomyelitis of the lower extremity: comparison of magnetic resonance imaging and combined bone scintigraphy/immunoscintigraphy with radiolabelled monoclonal antigranulocyte antibodies.**

[Kaim A.](#), [Ledermann HP.](#), [Bongartz G.](#), [Messmer P.](#), [Müller-Brand J.](#), [Steinbrich W.](#)

**For MRI,**

Sensitivity of 100%,

**Specificity of 60%,**

Accuracy of 79%,

PPV of 69%,

NPV of 100%.

Symposium zum Diabetischen Fuss  
27. Nov. 2015

Radiology. 1997 Jun;203(3):849-55.

Osteomyelitis of the diabetic foot: MR imaging-pathologic correlation.

Sensitivity 90%; specificity 71%.

## **CONCLUSION**

Marrow edema cannot be reliably distinguished from osteomyelitis with MR imaging.

## Role of magnetic resonance imaging in the evaluation of diabetic foot with suspected osteomyelitis

### *Ruolo della risonanza magnetica nello studio del piede diabetico con sospetta osteomielite*

U. Rozzanigo<sup>1</sup> • A. Tagliani<sup>1</sup> • E. Vittorini<sup>1</sup> • R. Pacchioni<sup>2</sup> • L. Renzi Brivio<sup>3</sup> • R. Caudana<sup>1</sup>



Fig. 2a-c Reactive bone marrow oedema of the talus and calcaneus due to neuropathy in a diabetic patient with mal perforans and normal radiographic findings [false-positive magnetic resonance imaging (MRI) diagnosis of osteomyelitis]. a The coronal T1-weighted turbo spin-echo (TSE) image with fat uppression after administration of paramagnetic contrast material reveals diffuse changes in signal intensity of bone marrow and soft tissues, as well as moderate contrast enhancement in the talus and in the subtalar portion of the calcaneus, wrongly interpreted as osteomyelitis associated with cellulitis. b



Symposium zum Diabetischen Fuß  
27. Nov. 2015



Symposium zum Diabetischen Fuss  
27. Nov. 2015



Symposium zum Diabetischen Fuss  
27. Nov. 2015



Symposium zum Diabetischen Fuss  
27. Nov. 2015



## Primarily non-surgical management of osteomyelitis of the foot in diabetes

F. L. Game • W. J. Jeffcoate

**Table 1** Twelve month outcomes in patients managed with antibiotics alone, compared with those managed with antibiotics plus minor amputation at initial presentation

Outcome	Antibiotics alone ( <i>n</i> =113)	Antibiotics with minor amputation ( <i>n</i> =28)
No recurrence of active disease	66 (58.4)	10 (35.7)
Recurrence or reactivation	35 (31.0)	17 (60.7)
Died	10 (8.8)	1 (3.6)
Lost to follow-up	2 (1.8)	0



# Antibiotics Versus Conservative Surgery for Treating Diabetic Foot Osteomyelitis: A Randomized Comparative Trial

José Luis Lázaro-Martínez,<sup>1</sup> Javier Aragón-Sánchez,<sup>2</sup> and Esther García-Morales<sup>1</sup>

## RESULTS

Eighteen patients (75%) achieved primary healing in the AG, and 19 (86.3%) in the SG ( $P = 0.33$ ). The median time to healing was 7 weeks (quartile [Q] 1 to Q5, Q3–Q8) in the AG and 6 weeks (Q1–Q3, Q3–Q9) in the SG ( $P = 0.72$ ). The conditions of four patients from the AG worsened (16.6%), and they underwent surgery. Three patients from the SG required reoperation. No difference was found between the two groups regarding minor amputations ( $P = 0.336$ ).



Contents lists available at ScienceDirect

## The Journal of Foot & Ankle Surgery

journal homepage: [www.jfas.org](http://www.jfas.org)



### The Effect of Residual Osteomyelitis at the Resection Margin in Patients with Surgically Treated Diabetic Foot Infection

Todd J. Kowalski, MD<sup>1</sup>, Miki Matsuda, DPM<sup>2</sup>, Matthew D. Sorenson, DPM<sup>2</sup>, Jacob D. Gundrum, MS<sup>3</sup>, William A. Agger, MD<sup>1</sup>

<sup>1</sup> Infectious Disease Physician, Section of Infectious Disease, Gundersen Lutheran Health System, La Crosse, WI

<sup>2</sup> Podiatrist, Department of Medical Education, Gundersen Lutheran Medical Foundation, La Crosse, WI

<sup>3</sup> Biostatistician, Department of Medical Research, Gundersen Lutheran Medical Foundation, La Crosse, WI

The Journal of Foot & Ankle Surgery 51 (2012) 749–752



Contents lists available at ScienceDirect

## The Journal of Foot & Ankle Surgery

journal homepage: [www.jfas.org](http://www.jfas.org)




### Rate of Residual Osteomyelitis after Partial Foot Amputation in Diabetic Patients: A Standardized Method for Evaluating Bone Margins with Intraoperative Culture

Said Atway, DPM<sup>1</sup>, Vincent S. Nerone, DPM<sup>2</sup>, Kevin D. Springer, DPM<sup>2</sup>, Darren M. Woodruff, DPM<sup>2</sup>

<sup>1</sup> Attending Podiatric Physician, The Ohio State University Medical Center, Columbus, OH

<sup>2</sup> Resident Podiatric Physician, The Ohio State University Medical Center, Columbus, OH





Symposium zum Diabetischen Fuss  
27. März 2015

**1. Diabetic foot osteomyelitis is an epiphenomena**


**2. All osteotitis does not heal withput reversing its cause**

Symposium zum Diabetischen Fuss  
27. Nov. 2015



Symposium zum Diabetischen Fuss  
27. Nov. 2015

# Arterial insufficiency




*Probabilité de cicatriser en fonction des résultats des explorations non invasives*



## Predictive Values of Transcutaneous Oxygen Tension for Above-the-ankle Amputation in Diabetic Patients with Critical Limb Ischemia

E. Faglia,<sup>1\*</sup> G. Clerici,<sup>1</sup> M. Caminiti,<sup>1</sup> A. Quarantiello,<sup>1</sup> V. Curci<sup>1</sup> and A. Morabito<sup>2</sup>

<sup>1</sup>Diabetology Center-Diabetic Foot Center, IRCCS Multimedica, Sesto San Giovanni, Milano, Italy, and



# Arteriobrachial index

## Valors:

- normal : 1.0-1.3
- 0.9-0.99 → limited
- 0.4-0.9 → probable obstruction
- <0.4 → obstruction and critical ischemia probable




– **No evidence for predicting the amputation level *per se***

Rooke, T. W. et al. "2011 Accf/Aha Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Catheter Cardiovasc Interv* 79, no. 4 (2012): 501-31.

Wyss, C. R., R. M. Harrington, E. M. Burgess and F. A. Matsen, 3rd. "Transcutaneous Oxygen Tension as a Predictor of Success after an Amputation." *J Bone Joint Surg Am* 70, no. 2 (1988): 203-7.

# TcPO<sub>2</sub>




Utilité clinique de la mesure transcutanée de la pression partielle d'oxygène, Sang Thrombose Vaisseaux. Volume 10, Numéro 9, 581-5, Novembre 1998, Mini-revues (<http://www.jle.com/e-docs/00/03/D0/AA/article.phtml>)

Byrne, P., J. L. Provan, F. M. Ameli and D. P. Jones. "The Use of Transcutaneous Oxygen Tension Measurements in the Diagnosis of Peripheral Vascular Insufficiency." *Ann Surg* 200, no. 2 (1984): 159-65.

# Amputations at HUG 2004-2014

## Re-amputations according to the prior level


	Forefoot	Syme	Leg	Knee	Calve
% (n)	13.9 (42)	2.1 (7)	50.8 (154)	9.24 (28)	23.8 (72)
Hard outcomes	45.2 (19)	57.1 (4)	22.7 (36)	25.0 (7)	18.1 (13)
% (n)					



- Amputations **below** the ankle:
  - Stratified between TcPO2 <**35 vs. ≥ 35mmHg**

tcPO2		Revision / Re-amputation		
		No	Yes	
>35	15	12		PPV = 56%
0-34	11	11		NPV = 50%
		Sensibility = 57.7%	Specificity = 47.8%	Accuracy = 53%

# Below ankle amputations: ROC = 0.52





IDSA LECTURE

## Counterpoint: Hyperbaric Oxygen for Diabetic Foot Wounds Is Not Effective

**A. R. Berendt**

Bone Infection Unit, Nuffield Orthopaedic Centre NHS Trust, Oxford, United Kingdom

---




Symposium zum Diabetischen Fuss  
27. Nov. 2015



# ANTIBIOTICS AND BONE PENETRATION

Landersdorfer CB et al. *Clin Pharmacokinet* 2009;48:89-124



CA = cancellous  
CO = cortical



- **Linezolid,**
  - **expensive**
  - **limited clinical data with RIF**

- **Streptogramins**

- **Daptomycin**

**Cliniquement pas supérieur aux vieux antibiotiques !**

**Etudes de non-infériorité.**

**Pas d'étude de supériorité in vivo !**


- **Minocycline, doxycycline**

- **Newer quinolones,**

- **better activity against *Staphylococci* sp than CIPRO**
- **studied above all in experimental models**

# IV antibiotics ?






THE COCHRANE  
COLLABORATION®

## Analysis 1.2. Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 2 Remission at least 12 months after the end of treatment.

Review: Antibiotics for treating chronic osteomyelitis in adults

Comparison: 1 Oral antibiotic versus parenteral antibiotic (AB)

Outcome: 2 Remission at least 12 months after the end of treatment



**Table 8. Suggested empirical antibiotic regimens, based on clinical severity, for diabetic foot infections.**

Route and agent(s)	Mild	Moderate	Severe
Advised route	Oral for most	Oral or parenteral, based on clinical situation and agent(s) selected	Intravenous, at least initially
Dicloxacillin	Yes	...	...
Clindamycin	Yes	...	...
Cephalexin	Yes	...	...
Trimethoprim-sulfamethoxazole	Yes	Yes	...
Amoxicillin/clavulanate	Yes	Yes	...
Levofloxacin	Yes	Yes	...
Cefoxitin	...	Yes	...
Ceftriaxone	...	Yes	...
Ampicillin/sulbactam	...	Yes	...
Linezolid <sup>a</sup> (with or without aztreonam)	...	Yes	...
Daptomycin <sup>a</sup> (with or without aztreonam)	...	Yes	...
Ertapenem	...	Yes	...
Cefuroxime with or without metronidazole	...	Yes	...
Ticarcillin/clavulanate	...	Yes	...
Piperacillin/tazobactam	...	Yes	Yes
Levofloxacin or ciprofloxacin with clindamycin	...	Yes	Yes
Imipenem-cilastatin	...	...	Yes
Vancomycin <sup>a</sup> and ceftazidime (with or without metronidazole)	...	...	Yes

# Choice of antibiotic agents

**Cheap, good oral bioavailability, good bone penetration, less side effects, oral**

- Clindamycin 3 x 600 mg p.o.
- Co-trimoxazol 2-3 x 960 mg (Bactrim forte)
- Augmentin 3 x 625-1000 mg
- In reserve: Ciprofloxacin 2 x 500-750 mg





# Duration of antibiotics ?





# Six-Week Versus Twelve-Week Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study

Diabetes Care 2015;38:302–307 | DOI: 10.2337/dc14-1514

Alina Tone,<sup>1</sup> Sophie Nguyen,<sup>1</sup>  
 Fabrice Devemy,<sup>2</sup> H  l  ne Topolinski,<sup>3</sup>  
 Michel Valette,<sup>1</sup> Marie Cazaubiel,<sup>4</sup>  
 Armelle Fayard,<sup>5</sup>   ric Beltrand,<sup>5</sup>  
 Christine Lemaire,<sup>3</sup> and   ric Senneville<sup>1</sup>

**Table 4—Clinical outcome of 40 diabetic patients with osteomyelitis of the foot treated nonsurgically according to the duration of antibiotic therapy**

Patient outcome	6 weeks n = 20	12 weeks n = 20	P
Overall remission	12 (60)	14 (70)	0.50
Complete healing*	18 (90)	16 (80)	0.38
Time to complete healing (weeks ± SD)	13.1 ± 12.2	16.8 ± 17.4	0.44
Overall failure	8 (40)	6 (30)	0.50
Noncomplete healing	2 (10)	4 (20)	0.37
Relapsing osteomyelitis	2 (10)	3 (15)	1
Worsening radiological bone abnormalities	6 (30)	4 (20)	0.46
Bone resection	2 (10)	2 (10)	1
Spread of osteomyelitis to contiguous sites	4 (20)	2 (10)	0.37
Major amputation	2 (10)	2 (10)	1

**Table 3—Antibiotic-related gastrointestinal adverse events reported in 40 diabetic patients with DFO treated nonsurgically according to the duration of antibiotic therapy**

Antibiotic-related adverse events	6 weeks n = 20	12 weeks n = 20
Nausea	1 (5)	2 (10)
Vomiting	1 (5)	2 (10)
Diarrhea	0	2 (10)
Hepatic cytolysis/cholestasis	1 (5)	3 (15)
Total	3 (15)	9 (45) <sup>#</sup>

Data are number of patients (%). <sup>#</sup>P = 0.04.

# IDSA DFI Guidelines: Revised (2012)

## IDSA GUIDELINES

### 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections<sup>a</sup>

**Benjamin A. Lipsky,<sup>1</sup> Anthony R. Berendt,<sup>2</sup> Paul B. Cornia,<sup>3</sup> James C. Pile,<sup>4</sup> Edgar J. G. Peters,<sup>5</sup> David G. Armstrong,<sup>6</sup> H. Gunner Deery,<sup>7</sup> John M. Embil,<sup>8</sup> Warren S. Joseph,<sup>9</sup> Adolf W. Karchmer,<sup>10</sup> Michael S. Pinzur,<sup>11</sup> and Eric Senneville<sup>12</sup>**

<sup>1</sup>Department of Medicine, University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle; <sup>2</sup>Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford; <sup>3</sup>Department of Medicine, University of Washington, Veteran Affairs Puget Sound Health Care System, Seattle; <sup>4</sup>Divisions of Hospital Medicine and Infectious Diseases, MetroHealth Medical Center, Cleveland, Ohio; <sup>5</sup>Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; <sup>6</sup>Southern Arizona Limb Salvage Alliance, Department of Surgery, University of Arizona, Tucson; <sup>7</sup>Northern Michigan Infectious Diseases, Petoskey; <sup>8</sup>Department of Medicine, University of Manitoba, Winnipeg, Canada; <sup>9</sup>Division of Podiatric Surgery, Department of Surgery, Roxborough Memorial Hospital, Philadelphia, Pennsylvania; <sup>10</sup>Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; <sup>11</sup>Department of Orthopaedic Surgery and Rehabilitation, Loyola University Medical Center, Maywood, Illinois; and <sup>12</sup>Department of Infectious Diseases, Dron Hospital, Tourcoing, France

---

Clinical Infectious Diseases 2012;54(12):132–173

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2012.

DOI: 10.1093/cid/cis346

**Table 11. Suggested Route, Setting, and Duration of Antibiotic Therapy, by Clinical Syndrome**

Site of Infection, by Severity or Extent	Route of Administration	Setting	Duration of Therapy
<b>Soft-tissue only</b>			
Mid	Topical or oral	Outpatient	1–2 wk; may extend up to 4 wk if slow to resolve
Moderate	Oral (or initial parenteral)	Outpatient/ inpatient	1–3 wk
Severe	Initial parenteral, switch to oral when possible	Inpatient, then outpatient	2–4 wk
<b>Bone or joint</b>			
No residual infected tissue (eg, postamputation)	Parenteral or oral	...	2–5 d
Residual infected soft tissue (but not bone)	Parenteral or oral	...	1–3 wk
Residual infected (but viable) bone	Initial parenteral, then consider oral switch	...	4–6 wk

Symposium zum Diabetischen Fuss  
27. Nov. 2015

# Few literature concernant « recurrence »

ISPUB.com / IJMB/10/2/14187

## INTERNET SCIENTIFIC PUBLICATIONS

HOME

JOURNALS

LATEST ARTICLES

DISCLAIMERS

ARTICLE SUBM

The Internet Journal of Microbiology

Volume 10

Number 2

Original Article

### Comparative Study of Community and Hospital Acquired Infections in Diabetic Foot

*S Pai, H Vijaykumar, M Sreevathsa, D Parag*

# 55 diabetic foot infections, surgery 84%

## 2 microbiological assessments: *On admission, and 1 week later.*

Table 1. First culture showing community acquired infections

Organisms isolated	Frequency (%) (n=55)
Klebsiella	14 (25.5)
E-coli	11 (20)
Enterococci	9 (16.4)
Proteus	4 (7.3)
Staphylococcus aureus	4 (7.3)
Enterobacter	3 (5.5)
Pseudomonas	1 (1.8)
Gram negative cocci	1 (1.8)
Non-fermenting gram neg bacilli	1 (1.8)
No growth	7 (12.7)

Table 3: Second culture showing hospital acquired infections.

Organism isolated	Frequency (%)
Pseudomonas	28 (50.9)
E. coli	8 (14.5)
Proteus	7 (12.7)
Gram positive cocci in pairs	4 (7.3)
Staphylococcus aureus	4 (7.3)
Non-fermenting gram negative bacilli	1 (1.8)
No growth	3 (5.5)



Symposium zum Diabetischen Fuss  
27. Juni 2015

# Retrospective study - results

- Among **517** episodes of DFI,
- Recurrence occurred in **244 (47%)**
- After a median of 2.4 yrs (range 60 days-5 yrs).
- Among these 244 recurrences,
- **157 (64%)** had isolates from their wounds that were not identified
- **(among the three main pathogens)** during the preceding episode.



## Article: Clinical Practice

# Does osteomyelitis in the feet of patients with diabetes really recur after surgical treatment? Natural history of a surgical series

J. Aragón-Sánchez<sup>1</sup>, J.L. Lázaro-Martínez<sup>2</sup>, C. Hernández-Herrero<sup>3</sup>, N. Campillo-Vilorio<sup>4</sup>, Y. Quintana-Marrero<sup>1</sup>, E. García-Morales<sup>2</sup> and M.J. Hernández-Herrero<sup>1</sup>

<sup>1</sup>Diabetic Foot Unit, La Paloma Hospital, Las Palmas de Gran Canaria, <sup>2</sup>Diabetic Foot Unit, Complutense University Clinic, Madrid <sup>3</sup>Endocrinology Department, University Macarena Hospital, Seville, Spain and <sup>4</sup>Diabetic Foot Unit, Diabetology Department, Plaza de la Salud General Hospital, Dominican Republic

64 patients: median duration of follow-up was 101.8 weeks

- Recurrence 4.6%
- Reulceration 43.0%
- New osteomyelitis 16.9%

# L'itinéraire clinique du pied diabétique infecté

bekr - 16.09.2014 11:12

**HUG**  
Hôpitaux Universitaires de Genève

**applications cliniques**  
support 24040 ou 372 4040

Modules Médicaux | Modules Spécialisés | **Itinéraires cliniques** | Modules Médico-techniques | Formation | Administration | Applications DIG

Ascite | Asthme | BPCO | Embolie pulmonaire | Insuffisance cardiaque | Leucémie aiguë/ Apla... | **Pied diabétique infecté** | Pneumonie acquise ... | Présentation des itinéraires...

**LE SYSTEME D'INFORMATION EST OPÉRATIONNEL**

**Laboratoires : Mise en œuvre des nouvelles étiquettes dès jeudi 10 juillet à 13h30** [nouvelles](#)

Dans le cadre de mise en place de l'automatisation des laboratoires (BATLab), la présentation des étiquettes a évolué. Il y a désormais une étiquette avec un numéro unique par tube. Il est important de respecter cette règle. Le format du papier reste le même. Pour les étiquettes imprimées avant ce changement, il n'y a pas besoin de ré-étiqueter, les laboratoires accepteront les anciennes étiquettes. [Pour plus de détails cliquez ici](#)

**Nouvelle version du résumé du dossier** [nouvelles](#)

**Désormais la trajectoire et les données administratives du patient se situent dans l'onglet "C" Cockpit médical.** [Pour plus de détails cliquez ici...](#)

# Etude sur l'intervention vasculaire sur 5 ans

## Echantillon sur 243 hospitalisations

- Nombre bilan angio : 144 (60%)
- Nombre CT angio : 59 (24%)
- Nombre colloque vasculaire : 43 (18%)
- Nombre interventions vasculaires: 36 (15%)

Délai admission-demande bilan angio :	médiane 0 jours	(fourchette 0-92 jours)
Délai demande-bilan angio :	médiane 0 jours	(fourchette 0-29 jours)
Délai bilan angio-CT :	médiane 5 jours	(fourchette 0-38 jours)
Délai CT-colloque :	médiane 5 jours	(fourchette -1-39 jours)
Délai colloque-intervention :	médiane 7 jours	(fourchette 1-25 jours)
Délai admission-intervention :	médiane 16 jours	(fourchette 4-24 jours)

# Prix séjour globaux et durées d'hospitalisation aiguë

2013	Nombres hospitalisations	Médian prix séjour par cas	Durée d'hospitalisation
<b>Tous les patients</b>	<b>200</b>	<b>20'206 CHF (1'407-300'269 CHF)</b>	<b>17 jours (1-190 jours)</b>
• Sans Caisson	172	18'475 CHF (1'407-178'322 CHF)	15 jours (1-138 jours)
• Avec Caisson	38	29'106 CHF (6'678-300'269 CHF)	36 jours (2-190 jours)
Ortho	68	28'151 CHF (5'145-132'731 CHF)	26 jours (2-118 jours)
Chir cardiovascul.	12	23'384 CHF (15'393-300'269 CHF)	16 jours (5-111 jours)
Médecine interne	77	14'553 CHF (2'636-178'322 CHF)	13 jours (1-100 jours)
• Angiologie	8	13'892 CHF (2'636-23'027 CHF)	5 jours (1-63 jours)
Dermatologie	7	76'041 CHF (31'815-160'968 CHF)	79 jours (35-130 jours)

# Several period prevalence studies

Median number of surgical interventions : 1

Median duration of antibiotics : 14 days

Median duration parenteral therapy: 2 days

Broad-spectrum antibiotic use: 92 episodes of 336 (27%)

2012 Infectious Diseases Society of America  
Clinical Practice Guideline for the Diagnosis  
and Treatment of Diabetic Foot Infections<sup>a</sup>


Benjamin A. Lipsky,<sup>1</sup> Anthony R. Berendt,<sup>2</sup> Paul B. Cornia,<sup>3</sup> James C. Pile,<sup>4</sup> Edgar J. G. Peters,<sup>5</sup> David G. Armstrong,<sup>6</sup>  
H. Gunner Deery,<sup>7</sup> John M. Embil,<sup>8</sup> Warren S. Joseph,<sup>9</sup> Adolf W. Karchmer,<sup>10</sup> Michael S. Pinzur,<sup>11</sup> and Eric Senneville<sup>12</sup>

<sup>1</sup>Department of Medicine, University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle; <sup>2</sup>Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford; <sup>3</sup>Department of Medicine, University of Washington, Veteran Affairs Puget Sound Health Care System, Seattle; <sup>4</sup>Divisions of Hospital Medicine and Infectious Diseases, MetroHealth Medical Center, Cleveland, Ohio; <sup>5</sup>Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; <sup>6</sup>Southern Arizona Limb Salvage Alliance, Department of Surgery, University of Arizona, Tucson; <sup>7</sup>Northern Michigan Infectious Diseases, Petoskey; <sup>8</sup>Department of Medicine, University of Manitoba, Winnipeg, Canada; <sup>9</sup>Division of Podiatric Surgery, Department of Surgery, Roxborough Memorial Hospital, Philadelphia, Pennsylvania; <sup>10</sup>Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; <sup>11</sup>Department of Orthopaedic Surgery and Rehabilitation, Loyola University Medical Center, Maywood, Illinois; and <sup>12</sup>Department of Infectious Diseases, Dron Hospital, Tourcoing, France




# Algorithme IC initial pied diabétique infecté 1/4

## Algorithme de prise en charge initiale d'un patient diabétique au pied infecté



# Algorithme IC initial pied diabétique infecté 4/4



*Merci beaucoup !!!*



Symposium zum Diabetischen Fuss  
27. Nov. 2015